Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Insilico Medicine, an AI Drug Company, Files for Hong Kong IPO

publication date: Apr 4, 2024

Insilico Medicine, an AI drug discovery-development company based in Hong Kong and New York, has completed an initial filing for a Hong Kong IPO. Insilico has developed several platforms that use generative AI to analyze biology, chemistry and clinical trials for next-gen AI systems. Formed in 2014, Insilico develops products for its own portfolio and out-licenses other candidates, while retaining their intellectual property. Two years ago, the company bragged that it needed only 30 months to move its lead drug from discovery to clinical trials at a cost of $2.5 million. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital